A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Part of paid clinical trials in Atlanta, Georgia.

Sponsor
Apellis Pharmaceuticals, Inc.
Study ID
NCT04901936
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Paroxysmal Hemoglobinuria
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)

Eligibility Criteria

Sex
ALL
Age
12 Years - 17 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to evaluate the safety, effectiveness, and biological activity (how the investigational medication is processed by the body) of pegcetacoplan in 12-17 year-olds (adolescents) who have paroxysmal nocturnal hemoglobinuria (PNH).

Key Dates

Start date
Feb 4, 2021
Status verified
Jun 2025
Primary completion
Dec 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
12 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pegcetacoplan

Primary Outcome Measure

Pegcetacoplan serum concentrations over the course of the 16-week treatment period [ Time Frame: 16 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Children's Hospital of AtlantaAtlantaGeorgia30329-

Find similar trials in Atlanta, GA

By research site
Children's Hospital of Atlanta· Atlanta, GA

Related Studies